Trinity Biotech plc (NASDAQ:TRIB) Short Interest Update

Trinity Biotech plc (NASDAQ:TRIB) saw a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 18,400 shares, an increase of 70.4% from the June 30th total of 10,800 shares. Based on an average daily trading volume, of 52,400 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.3% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Trinity Biotech in a report on Sunday, July 21st. They issued a “buy” rating on the stock.

Trinity Biotech Trading Down 3.7 %

Shares of NASDAQ TRIB traded down $0.11 during trading on Friday, reaching $2.88. 10,558 shares of the company traded hands, compared to its average volume of 67,522. The stock has a market cap of $21.95 million, a P/E ratio of -1.03 and a beta of 1.31. The firm’s fifty day simple moving average is $2.34 and its 200 day simple moving average is $2.21. Trinity Biotech has a 12-month low of $1.49 and a 12-month high of $5.10.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings results on Thursday, May 23rd. The company reported ($0.37) earnings per share for the quarter. The company had revenue of $14.70 million during the quarter. As a group, research analysts expect that Trinity Biotech will post -2.17 EPS for the current year.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.